Evolution and trends in non-viral mRNA Cancer vaccines: A scoping review from 2015 to 2025.
리뷰
1/5 보강
This scoping review synthesizes clinical trials from 2015 to 2025 investigating non-viral messenger RNA (mRNA)-based cancer vaccines, emphasizing trends in delivery platforms-ex vivo dendritic cell (D
- p-value p = 0.0025
- p-value p = 0.00042
APA
Nowzari F, Nowzari F, et al. (2026). Evolution and trends in non-viral mRNA Cancer vaccines: A scoping review from 2015 to 2025.. Vaccine, 71, 128059. https://doi.org/10.1016/j.vaccine.2025.128059
MLA
Nowzari F, et al.. "Evolution and trends in non-viral mRNA Cancer vaccines: A scoping review from 2015 to 2025.." Vaccine, vol. 71, 2026, pp. 128059.
PMID
41352221 ↗
Abstract 한글 요약
This scoping review synthesizes clinical trials from 2015 to 2025 investigating non-viral messenger RNA (mRNA)-based cancer vaccines, emphasizing trends in delivery platforms-ex vivo dendritic cell (DC) vaccines versus in vivo lipid-based systems-and their association with cancer types. A systematic search of PubMed and ClinicalTrials.gov identified 72 early-phase trials, revealing a significant shift from DC-based ex vivo approaches (dominant 2015-2020) to lipid nanoparticle (LNP)-based in vivo delivery post-2021 (p = 0.0025), propelled by advancements from COVID-19 vaccines. Statistical analyses, including linear regression and Fisher's exact test, demonstrate a strong association between ex vivo delivery and brain/CNS cancers (p = 0.00042) and no significant correlation between DC vaccine administration routes and cancer types (p = 0.25). The surge in combination immunotherapies, particularly with immune checkpoint inhibitors post-2019, underscores the field's move toward multimodal strategies. This article offers a data-driven roadmap of the field's evolution, highlighting gaps in delivery optimization, reporting transparency, and standardization for future research. Companion articles detail ex vivo DC vaccine strategies and in vivo mRNA vaccine advancements.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.